Skip to main content
Sign In
 

Stephen P. Hunger, MD

Professor of Pediatrics


Stephen P. Hunger, MD

Section Head, Hematology, Oncology and BMT
The Ergen Family Chair in Pediatric Cancer
Director, Center for Cancer and Blood Disorders
Associate Director, University of Colorado Cancer Center

Contact
   Phone: 720-777-8855
   E-mail: stephen.hunger@childrenscolorado.org

Affiliations
Section of Hematology, Oncology and BMT, Department of Pediatrics
Children's Hospital Colorado

Certifications
Pediatrics, Pediatric Hematology-Oncology

Medical Degree

  • University of Connecticut School of Medicine, 1985

Residency

  • Pediatrics, Johns Hopkins Hospital, 1985-1988

Fellowships

  • Pediatric Hematology/Oncology, Stanford University School of Medicine, 1988-1991
  • Postdoctoral Scholar (Research), Department of Pathology, Stanford University School of Medicine, 1991-1994

Dr. Hunger is an internationally recognized expert in leukemia genetics and the treatment of childhood  acute lymphoblastic leukemia (ALL). He serves as Chair of the Children's Oncology Group (COG) ALL Disease Committee, which is responsible for the design and conduct of clinical trials and linked laboratory research studies that include over 70% of U.S. and Canadian children with ALL. He is also Principal Investigator on the COG ALL TARGET project, which has identified a number of new molecular abnormalities in childhood ALL that hold promise as targets for new therapies.

Dr. Hunger is the Co-Principal Investigator of the Section of Hematology, Oncology and BMT's NIH-funded T32 grant to train pediatric cancer researchers.

  • Editorial Advisory Board, PDQ Pediatric Treatment, 2010-present
  • Guide to America's Top Oncologists, 2009-present
  • Guide to America’s Top Physicians, 2009-present
  • Best Doctors In America, 2008-present
  • Ergen Family Chair in Pediatric Cancer, 2007-present
  • Chairman, COG ALL Committee, 2007-present
  • Member, Society for Pediatric Research, 2003-present
  • Visiting Professor, Memorial Sloan Kettering Cancer Center, New York City, New York, 2011
  • Visiting Professor, Children's Hospital of Philadelphia, Pennsylvania,2011
  • Visiting Professor, Children's Mercy Hospital, Kansas City, Missouri, 2010
  • International Society of Paediatric Oncology (SIOP) Award for Basic Science Abstract, 2009
  • Editorial Board, Leukemia Research, 2009
  • Editorial Board, Pediatric Blood and Cancer, 2009

Publications in PubMed 

  • Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP, Min DJ, Potter JW, Harvey R, Hunger SP, Seibel N, Raetz EA, Pieters R, Horstmann MA, Relling MV, den Boer ML, Willman CL, Carroll WL. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: a Children's Oncology Group Study on behalf of the Dutch Childhood Oncology Group and the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2008 Sep;26(27):4376-84. [PMID: 18802149]
  • Graham DK, Hunger SP. BAC to the future? comparative genomic hybridization and genotyping pediatric leukemia cytogenetic abnormalities. Pediatr Blood Cancer. 2008 Aug;51(2):153-4. [PMID: 18300321]
  • Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol. 2008 Aug;26(24):3971-8. [PMID: 18711187]
  • Araya CE, Mehta MB, Gonzalez-Peralta RP, Hunger SP, Dharnidharka VR. Native kidney post-transplant lymphoproliferative disorder in a non-renal transplant patient. Pediatr Transplant. 2008 Jul 30. [PMID: 18673359]
  • Jackman KM, Frye CB, Hunger SP. Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008 Apr;50(4):772-8. [PMID: 18000861]
  • Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J, Bell B, Hunger SP, Chauvenet A, Pui CH, Camitta B, Pullen J. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study. J Clin Oncol. 2008 May;26(13):2186-91. [PMID: 18445843]
  • Abbatiello SE, Pan YX, Zhou M, Wayne AS, Veenstra TD, Hunger SP, Kilberg MS, Eyler JR, Richards NG, Conrads TP. Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients. J Proteomics. 2008 Apr;71(1):61-70. [PMID: 18541474]
  • Khan NI, Cisterne A, Devidas M, Shuster J, Hunger SP, Shaw PJ, Bradstock KF, Bendall LJ. Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics. Leuk Lymphoma. 2008 Apr;49(4):710-8. [PMID: 18398738]
  • Zhong CH, Prima V, Liang X, Frye C, McGavran L, Meltesen L, Wei Q, Boomer T, Varella-Garcia M, Gump J, Hunger SP. E2A-ZNF384 and NOL1-E2A fusion created by a cryptic t(12;19)(p13.3; p13.3) in acute leukemia. Leukemia. 2008 Apr;22(4):723-9. [PMID: 18185522]
  • Yang F, Li Y, Braylan R, Hunger SP, Yang LJ. Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. Pediatr Blood Cancer. 2008 Feb;50(2):415-8. [PMID: 17051534]
  • Su N, Pan YX, Zhou M, Harvey RC, Hunger SP, Kilberg MS. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer. 2008 Feb;50(2):274-9. [PMID: 17514734]
  • Henry DD, Hunger SP, Braylan RC, Dharnidharka VR. Low viral load post-transplant lymphoproliferative disease localized within the tongue. Transpl Infect Dis. 2008;10(6):426-30. [PMID: 18657087]
  • Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008;22(12):2142-50. [PMID: 18818707]
  • Yang JJ, Bhojwani D, Yang W, Cai X, Stocco G, Crews K, Wang J, Morrison D, Devidas M, Hunger SP, Willman CL, Raetz EA, Pui CH, Evans WE, Relling MV, Carroll WL. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008;112(10):4178-83. [PMID: 18768390]
  • Prima V, Hunger SP. Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia. 2007 Dec;21(12):2470-5. [PMID: 17898785]
  • Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 2007 Mar;13(6):1783-8. [PMID: 17363533]
  • Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb;109(3):926-35. [PMID: 17003380]
  • Keole S, Hunger SP. Management of anaplastic histology Wilms’ Tumor: the impact of NWTS-5. Am J Hematol Onc. 2007;6:79-81
  • Prima V, Gore L, Caires A, Boomer T, Yoshinari M, Imaizumi M, Varella-Garcia M, Hunger SP. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia. 2005 May;19(5):806-13. [PMID: 15744350]
  • Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Proytcheva MA, Hunger SP, Malcolm J, Schissel D, Hild E, Giller RH. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant. 2005 Jan;35(2):143-9. [PMID: 15558042]